Eli Lilly's rapid growth has been linked to its deep and varied roster of leading pharmaceutical products, including Trulicity and Mounjaro (treatments for diabetes) and Prozac and Cymbalta ...

Eli Lilly shares dropped after the drugmaker cut its 2024 revenue guidance, citing lower-than-expected demand for its obesity and diabetes drugs.

We are looking forward to working together to discover and develop novel targets and therapies for ALS patients." Under the terms of the agreement, Alchemab will collaborate with Lilly to discover ...